341 related articles for article (PubMed ID: 24812274)
1. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation.
Raha D; Wilson TR; Peng J; Peterson D; Yue P; Evangelista M; Wilson C; Merchant M; Settleman J
Cancer Res; 2014 Jul; 74(13):3579-90. PubMed ID: 24812274
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.
Casagrande N; De Paoli M; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Gynecol Oncol; 2013 Dec; 131(3):744-52. PubMed ID: 24029417
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44⁺ human breast cancer cells.
Croker AK; Allan AL
Breast Cancer Res Treat; 2012 May; 133(1):75-87. PubMed ID: 21818590
[TBL] [Abstract][Full Text] [Related]
4. Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy.
Nishikawa S; Konno M; Hamabe A; Hasegawa S; Kano Y; Ohta K; Fukusumi T; Sakai D; Kudo T; Haraguchi N; Satoh T; Takiguchi S; Mori M; Doki Y; Ishii H
Int J Oncol; 2013 Apr; 42(4):1437-42. PubMed ID: 23440340
[TBL] [Abstract][Full Text] [Related]
5. Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer.
Kim JY; Cho Y; Oh E; Lee N; An H; Sung D; Cho TM; Seo JH
Cancer Lett; 2016 Aug; 379(1):39-48. PubMed ID: 27238567
[TBL] [Abstract][Full Text] [Related]
6. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.
Huang H; Liao Y; Liu N; Hua X; Cai J; Yang C; Long H; Zhao C; Chen X; Lan X; Zang D; Wu J; Li X; Shi X; Wang X; Liu J
Oncotarget; 2016 Jan; 7(3):2796-808. PubMed ID: 26625200
[TBL] [Abstract][Full Text] [Related]
7. ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
Huang CP; Tsai MF; Chang TH; Tang WC; Chen SY; Lai HH; Lin TY; Yang JC; Yang PC; Shih JY; Lin SB
Cancer Lett; 2013 Jan; 328(1):144-51. PubMed ID: 22935675
[TBL] [Abstract][Full Text] [Related]
8. Reversing the intractable nature of pancreatic cancer by selectively targeting ALDH-high, therapy-resistant cancer cells.
Kim SK; Kim H; Lee DH; Kim TS; Kim T; Chung C; Koh GY; Kim H; Lim DS
PLoS One; 2013; 8(10):e78130. PubMed ID: 24194908
[TBL] [Abstract][Full Text] [Related]
9. Disulfiram/copper targets stem cell-like ALDH
Jin N; Zhu X; Cheng F; Zhang L
J Cell Biochem; 2018 Aug; 119(8):6882-6893. PubMed ID: 29665144
[TBL] [Abstract][Full Text] [Related]
10. Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.
Yang Z; Guo F; Albers AE; Sehouli J; Kaufmann AM
Biomed Pharmacother; 2019 May; 113():108727. PubMed ID: 30870721
[TBL] [Abstract][Full Text] [Related]
11. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Xie M; He CS; Wei SH; Zhang L
Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
[TBL] [Abstract][Full Text] [Related]
12. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells.
Liu P; Brown S; Goktug T; Channathodiyil P; Kannappan V; Hugnot JP; Guichet PO; Bian X; Armesilla AL; Darling JL; Wang W
Br J Cancer; 2012 Oct; 107(9):1488-97. PubMed ID: 23033007
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation.
Guo F; Yang Z; Kulbe H; Albers AE; Sehouli J; Kaufmann AM
Biomed Pharmacother; 2019 Oct; 118():109371. PubMed ID: 31545281
[TBL] [Abstract][Full Text] [Related]
15. Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity.
Wang L; Park P; Zhang H; La Marca F; Lin CY
Int J Cancer; 2011 Jan; 128(2):294-303. PubMed ID: 20309879
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
[TBL] [Abstract][Full Text] [Related]
17. ROS activated prodrug for ALDH overexpressed cancer stem cells.
Won M; Kim JH; Ji MS; Kim JS
Chem Commun (Camb); 2021 Dec; 58(1):72-75. PubMed ID: 34874378
[TBL] [Abstract][Full Text] [Related]
18. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
19. Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors.
Choi SA; Choi JW; Wang KC; Phi JH; Lee JY; Park KD; Eum D; Park SH; Kim IH; Kim SK
Neuro Oncol; 2015 Jun; 17(6):810-21. PubMed ID: 25378634
[TBL] [Abstract][Full Text] [Related]
20. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis.
Marcato P; Dean CA; Pan D; Araslanova R; Gillis M; Joshi M; Helyer L; Pan L; Leidal A; Gujar S; Giacomantonio CA; Lee PW
Stem Cells; 2011 Jan; 29(1):32-45. PubMed ID: 21280157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
